November 2025 Prescription Drug Affordability Board Meeting

• Date and time: November 17th, 2025 10:00 am
• Address:

  Miller Senate Building, William Amoss Room, 4th Floor
  11 Bladen Street
  Annapolis, MD 21401
  United States

Public Comment

The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email [email protected]​ no later than the close of business on Wednesday, November 12, 2025, and provide:

1. Your name
2. Your address
3. The agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation or provide additional detail.

Written Comment

The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to [email protected]. Please include in the subject line: November 2025 Board Meeting Comments. Please submit any written comments concerning this agenda no later than the close of business on Wednesday, November 12, 2025.

Agenda and Meeting Materials

• ​A​gen​da - PDF - 156.05 KB
• Minute​s - PDF - 182.06 KB
• Meeting Re​cording
• Overview of Cost Review Study Process and Policy Review Process​- Presentation - PDF - 390.94 KB
• Jardiance: Upper Payment Limit Framework (11/4/2025) - PDF - 244.7 KB
• Jardiance: Upper Payment Limit Framework- Presentation - PDF - 239.99 KB
• Farxiga: Up​per Payment Limit Framework (11/4/2025)​​ - PDF - 236.96 KB
• Farxiga: Upper Payment Limit Framework- Presentation - PDF - 239.5 KB​
• Ozempic Cost Review Study- Presentation - PDF - 5.72 MB
• Trulicity Cost Review Study- Presentation - PDF - 5.68 MB

Ozempic Dossier Information* (POSTED 11/4/2025)- UPDATED (NEW)

*Also posted as meeting materials for the November 17, 2025 Board Meeting​

• ​November 4, 2025 Ozempic Dossier - PDF - 10.04 MB​
  • Exhibit 1 Pricing History REDACTED ​​ - PDF - 295.1 KB
  • Exhibit 2 RFI Submissions (NON-PUBLIC--TRADE SECRET, ​CONFIDENTIAL, AND PROPRIETARY) ​
  • Exhibit 3​ Ozempic Therapeutic Alternative Pricing REDACTED - XLSX - 306.33 KB
  • Exhibit 4 Ozempic Therapeutic Alternative Medical Claims Data Base (MCDB) Statistics - XLSX - 150.18 KB
  • Exhibit 5
    • Exhibit 5A Ozempic Summary of Cost Effectiveness Analyses - XLSX - 19.9 KB
    • Exhibit 5B Ozempic Summary of Comparative Effectiveness Research  - XLSX - 25.69 KB
  • Exhibit 6
    • Exhibit 6A Written Comments (60-day COMAR 14.01.04.05C(2)) - PDF - 1.03 MB
    • Exhibit 6B Written Comments (Request October 28, 2024) - PDF - 239.76 KB
    • Exhibit 6C Written Comments (Request September 4, 2025) - PDF - 1.46 MB

Trulicity Dossier Information* (POSTED 11/4/2025)- UPDATED (NEW) 

*Also posted as meeting materials for the November 17, 2025 Board Meeting

• ​November 4, 202​5 Trulicity Dossier​ - PDF - 3.63 MB
  • Exhibit 1 Pricing History REDACTED - PDF - 323.09 KB
  • Exhibit 2 RFI Submissions (NON-PUBLIC--TRADE SECRET, ​CONFIDENTIAL, AND PROPRIETARY) ​
  • Exhibit 3​ Trulicity Therapeutic Alternative Pricing REDACTED - XLSX - 306.31 KB
  • Exhibit 4 Trulicity Therapeutic Alternative Medical Claims Data Base (MCDB) Statistics - XLSX - 150.18 KB
  • Exhibit 5
    • Exhibit 5A Trulicity Summary of Cost Effectiveness Analyses - XLSX - 17.95 KB
    • Exhibit 5B Trulicity Summary of Comparative Effectiveness Research - XLSX - 23.01 KB
  • Exhibit 6
    • Exhibit 6A Written Comments (60-day COMAR 14.01.04.05C(2)) - PDF - 1.17 MB
    • Exhibit 6B Written Comments (Request October 28, 2024) - PDF - 239.63 KB
    • Exhibit 6C Written Comments (Request September 4, 2025) - PDF - 1.36 MB

Comments Received from the following:

Written Comment Packet - PDF - 2.37 MB

• AARP
• AstraZeneca​
• Boehringer Ingelheim
• Committee to Protect Healthcare
• Community Access National Network
• Diabetes Patient Advocacy Coalition
• EACH/PIC Coalition
• Larry Zarzecki
• Let My Doctors Decide Action Network
• Lilly
• Maryland Healthcare for All Coalition
• Maryland NARFE Federation
• Value of Care Coalition